Home / People / Niall McAlister
Portrait ofNiall McAlister

Niall McAlister

Partner

CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
Languages English

Niall McAlister is a partner in the Corporate/M&A Team at CMS London. With over thirty years' experience as a corporate lawyer, Niall has particular expertise in mergers and acquisitions, joint ventures and private equity and venture capital transactions.  He has a particular focus on the Life Sciences & Healthcare sector. He has led teams on a number of substantial cross-border transactions. He is experienced in representing life sciences clients, having advised both commercial entities and medical research charities on a range of transactions in the sector. He is recognised in directories for his expertise both as a corporate lawyer in the life sciences sector and as a charity lawyer. 

more less

"Recommended for transactions and venture capital investments in the life science sector."

Legal 500

Relevant experience

  • The owners of Aspine Pharma on the buy-out of the company to HIG Capital.
  • Contura Holdings on the sale of its women's health business to Axonics Modulation Technologies for up to USD 230m.
  • The owners of iPlato on its sale to Huma Therapeutics.
  • The owners of Sirakoss on the sale of the company to OssDsign.
  • Syncona on the sale of Blue Earth Diagnostics to Bracco Imaging for $450m.
  • The owners of a generic therapeutics business on its sale to a private equity purchaser.
  • The owners of Birken AG on its sale to Amryt Pharmaceuticals.
  • The managers of Speciality European Pharmaceuticals on the management buy-out of the company from a consortium of investors led by Advent Partners.
  • A leading biologics developer on a substantial joint venture with a global pharmaceutical company to develop a biosimilar to a "blockbuster" therapeutic.
  • The owners of Antitope on the sale of the company to PolyTherics.
  • The owners of Luminescence, a manufacturer of high-quality security inks, on the sale of the company to Sun Chemicals.
  • The owners of a speciality pharmaceuticals and medical device business on a three-way demerger of the business.
  • Integra Lifesciences on various reorganisations of its European business.
  • Gyroscope Therapeutics on its Series B investment round.
  • Epidarex Capital on a range of early-stage investments including in Lazo Therapeutics, Kynos Therapeutics, Theolytics, Dunad Therapeutics, Curve Therapeutics, Mironid, Leucid Bio, Lunac Therapeutics, EM Imaging, Enterprise Therapeutics and Topas Therapeutics.
  • ALSA Holdings and Albion Capital on their Series A investment in iGem Therapeutics.
  • SR One and Longwood Fund on their investment in Pulmocide.
  • Astellas Venture Managers on its investments in F2G, Bicycle Therapeutics and Crescendo Biologics.
  • The Wellcome Trust on a number of venture capital investments in European biotech and medical device companies.
  • A number of early-stage companies, including AdoRx Pharmaceuticals, Nugeronlix, Lunac Therapeutics, Sirahoss and Michelson Diagnostics, on investment rounds.
  • A major international pharmaceutical company on its auction bid for a substantial European pharmaceutical business.
  • A client on European aspects of the buy-out of a global medical imaging business and on the subsequent group restructuring.
  • Astex Therapeutics on its investment into the Dementia Discovery Fund, a limited partnership established to develop therapies for dementia and related conditions.
  • UKCMRI Limited on its negotiation of the joint venture with the MRC, Cancer Research UK, the Wellcome Trust and Imperial College London to create the Crick Institute.
  • The Wellcome Trust on its joint venture with GSK to develop the Stevenage Bioscience Incubator.
more less

Education

  • 1986 – LL.B., University of Bristol, Bristol
more less

Feed

18/12/2023
CMS Expert Guide to digital health apps and telemedicine
Digitisation is advancing steadily. Its pioneering innovations challenge all parties involved. One of the most important aspects in this area is the huge potential that lies in the digitisation of healthcare...
Comparable
12/06/2023
CMS updates Global Expert Guide to Digital health apps and telemedicine
Digitisation is advancing steadily. Its pioneering innovations challenge all parties involved.One of the most important aspects in this area is the huge potential that lies in the digitisation of healthcare.In...
14/12/2020
CMS Global Expert Guide to Digital health apps and telemedicine
Digitisation is advancing steadily. Its pioneering innovations challenge all parties involved. One of the most important aspects in this area is the huge potential that lies in the digitisation of healthcare...
28/07/2020
CMS On the Pulse episode #4: Digital health law, regulations and developments...
The Global Life Sciences & Healthcare Sector Group is delighted to launch the latest episode in its new video/podcast series, On the Pulse. The series brings together CMS lawyers and experts to discuss...
08/07/2020
CMS On the Pulse episode #3: Digital health law, regulations and developments...
The Global Life Sciences & Healthcare Sector Group is delighted to launch the latest episode in its new video/podcast series, On the Pulse. The series brings together CMS lawyers and experts to discuss...
11/05/2020
AI in Life Sciences
Artificial intelligence is not new: the term itself was coined over 60 years ago. However, the convergence of data volume, processing power and technical capability has convinced many that the AI era...
01/07/2019
CMS advises sellers in relation to $450m sale of Blue Earth Diagnostics
International law firm CMS has advised the sellers in relation to the sale of Blue Earth Diagnostics to diagnostic imaging business Bracco Imaging. Bracco Imaging will acquire all outstanding shares of...
27/06/2019
AI in Life Sciences
At CMS, we have many lawyers in many countries thinking about the increasing impact of AI on the life sciences legal landscape. Rather than keep these thoughts to ourselves, we thought we would share...
20/12/2018
Launch of Life Sciences Sector Deal 2
The Industrial Strategy – Life Sciences Sector Deal 2 report is broken down by themes with each identifying what progress has been made by each of the sector and Government. A summary of these themes...
17/12/2018
Transforming health and social care
Industry perspectives on the opportunities and challenges of AI At a roundtable event in London in September 2018, CMS assembled a selection of healthcare operators, industry experts, healthtech companies...
21/03/2017
Olswang advises two new VC clients on Series B investment round in British...
This article was produced by Olswang LLP, which joined with CMS on 1 May 2017. International technology, media and telecoms law firm Olswang has advised venture capital firms SR One Ltd and Longwood Fund...
03/10/2014
Olswang boosts Life Sciences offering with new corporate partner
This article was produced by Olswang LLP, which joined CMS on 1 May 2017. International law firm Olswang has announced that Niall McAlister joined the firm on 29 September as a corporate partner in its...